337O - The changes in the treatment of elderly AML patients in Korea: A single center experience

Date 19 December 2016
Event ESMO Asia 2016 Congress
Session Haematological malignancies
Topics Anticancer Agents
Geriatric Oncology
Presenter Hyewon Ryu
Citation Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586
Authors I. Song, Y.S. Choi, H. Ryu, S.W. Baek, J.Y. Moon, H.J. Lee, H.J. Yun, S. Kim, D.Y. Jo
  • Internal Medicine, Chungnam National University Hospital, 301-721 - Daejeon/KR



Decitabine have been used widely in the elderly AML patients, since the National Health Insurance system started to cover it in the November 2013 in Korea. This study was conducted to review the changes of the treatment pattern and draw the better treatment strategies.


This study enrolled patients who were newly diagnosed with AML aged ≥65 years between 2010 and 2015 at Chungnam National University Hospital. The primary end point was overall survival, and the secondary end points were complete response (CR) rate, 1-year survival rate, and early mortality (death within 2 months).


In total, 42 patients were diagnosed with AML from Jan. 2011 to Oct. 2013 and 26 patients from Nov. 2013 to Dec. 2015. After the insurance of decitabine, the patients were treated with any kind of chemotherapy more frequently than before (84.6% v 54.8%, respectively, p 


These results indicate that decitabine is a reasonable treatment option in patients with age ≥70 years and WBC counts

Clinical trial indentification

Legal entity responsible for the study

Chungnam National University Hospital IRB


Chungnam National University Hospital


All authors have declared no conflicts of interest.